Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether NHS England or NHSBSA have identified any gaps or inconsistencies in national prescribing or outcomes data relating to puberty blockers in under-18s.

In March 2024, NHS England published a suite of documentation relating to its decision to remove gonadotrophin releasing hormone analogues as a routine treatment option in the National Health Service for children under 18 years old with gender dysphoria. This documentation included a review of the published evidence, which concluded that there is very limited evidence about safety, risks, benefits, and outcomes for the use of this medication in children with gender dysphoria. Restrictions on the sale and supply of these medicines via private and NHS prescriptions were introduced in May 2024.

In line with the findings and recommendations of the Cass Review, NHS England and the National Institute for Health and Care Research have commissioned a carefully designed clinical trial to assess the relative benefits and harms of puberty suppressing hormones on young people’s physical, social, and emotional well-being.

With regard to national prescribing data, the Government holds information relating to NHS prescriptions of gonadotropin hormone-releasing hormone agonists for all purposes for children aged 17 years old and under that were prescribed and dispensed in community pharmacies or general practices in England in each year from 2015/16 to September 2025. The NHS Business Services Authority does not hold patient data prior to April 2015.

The Government does not hold data for prescriptions dispensed within secondary care, prisons, or other detention centres, or private prescriptions other than controlled drugs.